Form 4: MaxCyte Director William Brooke Receives Annual Equity Grant

MaxCyte, Inc. Director William W. Brooke was granted 29,210 restricted stock units and 50,790 stock options as part of his annual compensation, vesting on June 18, 2026.

Summary

• William W. Brooke, a Director of MaxCyte, Inc. (MXCT), received an annual equity grant.
• The grant, dated June 18, 2025, includes 29,210 restricted stock units (RSUs) and 50,790 stock options.
• Each RSU represents a contingent right to receive one share of MaxCyte's Common Stock.
• The stock options have an exercise price of $2.11 and expire on June 17, 2035.
• These grants were made under the Issuer's Equity Grant Policy for non-employee directors.
• The shares underlying this grant are scheduled to vest on June 18, 2026, contingent upon Mr. Brooke's continuous service.
• Following these transactions, Mr. Brooke beneficially owns 100,879 shares of Common Stock and 50,790 stock options directly.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is a positive sign of aligning management interests with shareholders and is part of standard compensation practices. No negative information is present.

Positives

• The grant of 29,210 restricted stock units (RSUs) and 50,790 stock options aligns the director's interests with long-term shareholder value.
• The equity grant is part of the company's established Equity Grant Policy for non-employee directors, indicating a structured approach to compensation.
• The vesting schedule, contingent on continuous service until June 18, 2026, promotes director retention and commitment.

Risks

• The vesting of the granted shares is subject to the reporting person's continuous service as of June 18, 2026, meaning the shares could be forfeited if service ceases before this date.
• The value of the stock options and RSUs is dependent on the future performance of MaxCyte's stock price.

Future Outlook

The vesting of the granted equity on June 18, 2026, indicates a future milestone for the director's compensation, contingent on continued service. The stock options have a long-term expiration date of June 17, 2035, providing a long-term incentive.

Industry Context

This is a standard director compensation filing, common across publicly traded companies, particularly in the biotechnology or life sciences sector where equity-based compensation is prevalent to align director interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to a non-employee director is a common practice in the U.S. public company landscape, particularly within the biotech and life sciences industries, to attract and retain qualified board members.
• The structure of the grant, including a vesting period and a long-term option expiration, aligns with typical incentive compensation plans designed to promote long-term commitment and performance alignment.
• Specific comparable companies or projects are not mentioned in the document, so a direct comparison of the size of the grant to industry benchmarks would require external data not provided here. However, the type of compensation is standard.

Corporate Governance

Related Party Transactions

• The grant of equity (restricted stock units and stock options) by MaxCyte, Inc. to William W. Brooke, a director of the company, constitutes a related party transaction as it involves compensation provided to a member of the board.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with those of shareholders, as the value of the compensation is tied to the company's stock performance. It also represents a dilution of existing shares upon vesting and exercise, though this is a standard component of equity compensation plans.

Next Steps

• The restricted stock units are scheduled to vest on June 18, 2026, subject to the director's continuous service.

Key Dates

Recommendation

Keywords

MaxCyte, MXCT, SEC Form 4, Director Compensation, Equity Grant, Restricted Stock Units, RSUs, Stock Options, Insider Transaction, Corporate Governance, Executive Compensation